Davis J - Search Results

1

Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.

Keller C, Webb A, Davis J. Keller C, et al. Among authors: davis j. Ann Rheum Dis. 2003 Dec;62(12):1128-32. doi: 10.1136/ard.2003.011023. Ann Rheum Dis. 2003. PMID: 14644847 Free PMC article. Review.

2

The use of topical tacrolimus (FK506/Protopic) in cutaneous manifestations of autoimmune diseases.

Graf J, Webb A, Davis J. Graf J, et al. Among authors: davis j. J Clin Rheumatol. 2003 Oct;9(5):310-5. doi: 10.1097/01.rhu.0000089788.92835.dc. J Clin Rheumatol. 2003. PMID: 17041481

3

Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil.

Gehi A, Webb A, Nolte M, Davis J Jr. Gehi A, et al. Among authors: davis j jr. Arthritis Rheum. 2003 Apr;48(4):1067-70. doi: 10.1002/art.10879. Arthritis Rheum. 2003. PMID: 12687550 Free article.

4

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.

Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH. Davis JC Jr, et al. Ann Rheum Dis. 2008 Mar;67(3):346-52. doi: 10.1136/ard.2007.078139. Epub 2007 Oct 29. Ann Rheum Dis. 2008. PMID: 17967833 Free article. Clinical Trial.

5

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.

Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC Jr. Maksymowych WP, et al. J Rheumatol. 2005 Oct;32(10):1911-7. J Rheumatol. 2005. PMID: 16206346 Clinical Trial.

6

Results from an open-label extension study of etanercept in ankylosing spondylitis.

Davis J Jr, Webb A, Lund S, Sack K. Davis J Jr, et al. Arthritis Rheum. 2004 Apr 15;51(2):302-4. doi: 10.1002/art.20241. Arthritis Rheum. 2004. PMID: 15077279 Free article. Clinical Trial. No abstract available.

7

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.

Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W. Davis JC, et al. Ann Rheum Dis. 2005 Nov;64(11):1557-62. doi: 10.1136/ard.2004.035105. Epub 2005 Apr 20. Ann Rheum Dis. 2005. PMID: 15843448 Free PMC article.

8

Definition of disease duration in ankylosing spondylitis: reassessing the concept.

Davis JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. Davis JC, et al. Ann Rheum Dis. 2006 Nov;65(11):1518-20. doi: 10.1136/ard.2005.044834. Epub 2006 Feb 7. Ann Rheum Dis. 2006. PMID: 16464987 Free PMC article.

9

Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort.

Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC Jr. Gensler LS, et al. Among authors: davis jc jr. Ann Rheum Dis. 2008 Feb;67(2):233-7. doi: 10.1136/ard.2007.072512. Epub 2007 Jun 29. Ann Rheum Dis. 2008. PMID: 17604288

10

New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate.

Davis JC Jr, Huang F, Maksymowych W. Davis JC Jr, et al. Rheum Dis Clin North Am. 2003 Aug;29(3):481-94, viii. doi: 10.1016/s0889-857x(03)00028-0. Rheum Dis Clin North Am. 2003. PMID: 12951863 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,879 results

Search Page

Filters